Lamisil Poses Serious Health Risks: Report

Law360, New York (February 13, 2008, 12:00 AM EST) -- Novartis AG's oral fungal infection treatment Lamisil appears to put patients at risk of serious, and even life-threatening, liver, blood and skin problems, an Australian health regulator has reported.

The Australian Adverse Drug Reactions Advisory Committee said earlier this month that it had received 722 reports of harmful side effects from terbinafine, an oral version of the cream used to treat skin and nail fungal infections, sold under the brand name Lamisil. Three of those patients died from liver failure.

ÔÇťADRAC reminds prescribers that oral terbinafine...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.